afamelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Peptide YY (PYY), also known as peptide tyrosine tyrosine, is a peptide that in humans is encoded by the PYY gene. Peptide YY is a short (36-amino acid) peptide released from cells in the ileum and colon in response to feeding. In the blood, gut, and other elements of periphery, PYY acts to reduce appetite; similarly, when injected directly into the central nervous system, PYY is also anorexigenic, i.e., it reduces appetite. Dietary fibers from fruits, vegetables, and whole grains, consumed, increase the speed of transit of intestinal chyme into the ileum, to raise PYY3-36, and induce satiety. Peptide YY cannot be produced as the result of enzymatic breakdown of crude fish proteins and ingested as a food product.
Collins described her return to the show as "redemption" after withdrawing from her original series, comparing herself to Lara Croft and noted that although the series was tougher this time around, she felt she had "unfinished business" and ultimately "shut it down". She entered camp on the second day of the series alongside Craig Charles, who had also appeared on her original series. Collins completed a helicopter ride into camp, before she and Charles took part in an eating trial, which was won by the latter. She resided in the basic camp "Savannah Scrub" alongside Adam Thomas, Beverley Callard and Seann Walsh for several days, until they joined the main camp after completing a trial in which they were situated in water tanks and had to transport keys to one another. Following her arrival in main camp, Collins fell out of her hammock during one of the episodes. She completed her third trial alongside Scarlett Moffatt, during which time the camp was split into teams. She ultimately lost this trial; however her team the "Rhinos" were victorious and ultimately won a banquet and a trip on safari. Following a safety chain elimination in which Collins was saved by Jimmy Bullard and David Haye was eliminated, Haye then had to choose another campmate to leave alongside him. He chose Collins, who ultimately became the third campmate to be eliminated from the series after spending nine days in camp. Later in the year, Collins is set to begin starring in a Sky One reality series, Gemma Collins: Everything.
=== Neuropathic pain === Gabapentin is recommended as a first-line treatment for chronic neuropathic pain by various medical authorities. This is a general recommendation applicable to all neuropathic pain syndromes except for trigeminal neuralgia, where it may be used as a second- or third-line agent. Regarding the specific diagnoses, a systematic review has found evidence for gabapentin to provide pain relief for some people with postherpetic neuralgia and diabetic neuropathy. Gabapentin is approved for the former indication in the US. In addition to these two neuropathies, European Federation of Neurological Societies guideline notes gabapentin effectiveness for central pain. A combination of gabapentin with an opioid or nortriptyline may work better than either drug alone. Evidence finds little or no benefit and significant risk in those with chronic low back pain or sciatica. Gabapentin is not effective in HIV-associated sensory neuropathy and neuropathic pain due to cancer.
== Chemistry and mechanism of action == Teduglutide differs from natural GLP-2 by a single amino acid: an alanine is replaced with a glycine. This blocks breaking down of the molecule by dipeptidyl peptidase and increases its half-life from seven minutes (GLP-2) to about two hours, while retaining its biological actions. These include maintenance of the intestinal mucosa, increasing intestinal blood flow, reducing gastrointestinal motility and secretion of gastric acid.
Sources: en.wikipedia.org
=== French === During the war, there were many instances of war rapes against Vietnamese civilians by French soldiers. This occurred in Saigon, alongside robberies and killings, following the return of the French in August 1945. Vietnamese women were also raped by French soldiers in northern Vietnam in 1948, following the defeat of the Viet Minh, including in Bảo Hà, Bảo Yên District, Lào Cai province and Phu Lu. This led to 400 French-trained Vietnamese defecting to the Viet Minh in June 1948. French killings of Vietnamese civilians were reported, many of them were caused by the tendency of Viet Minh troops to hide among civilian settlements. One of the largest massacres by French troops was the Mỹ Trạch massacre of November 29, 1947, in which French soldiers killed over 200 women and children. Regarding this massacre and other atrocities during the conflict, Christopher Goscha wrote in The Penguin History of Modern Vietnam:Rape became a disturbing weapon used by the Expeditionary Corps, as did summary executions. Young Vietnamese women who could not escape approaching enemy patrols smeared themselves with any stinking thing they could find, including human excrement. Decapitated [sic] heads were raised on sticks, bodies were gruesomely disemboweled, and body parts were taken as 'souvenirs'; Vietnamese soldiers of all political color also committed such acts. The non-communist nationalist singer, Phạm Duy, wrote a bone-chilling ballad about the mothers of Gio Linh village in central Vietnam, each of whom had lost a son to a French Army massacre in 1948.
=== Glycolysis === When more R5P is needed than NADPH, R5P can be formed through glycolytic intermediates. Glucose 6-phosphate is converted to fructose 6-phosphate (F6P) and glyceraldehyde 3-phosphate (G3P) during glycolysis. Transketolase and transaldolase convert two molecules of F6P and one molecule of G3P to three molecules of R5P. During rapid cell growth, higher quantities of R5P and NADPH are needed for nucleotide and fatty acid synthesis, respectively. Glycolytic intermediates can be diverted toward the non-oxidative phase of PPP by the expression of the gene for pyruvate kinase isozyme, PKM. PKM creates a bottleneck in the glycolytic pathway, allowing intermediates to be utilized by the PPP to synthesize NADPH and R5P. This process is further enabled by triosephosphate isomerase inhibition by phosphoenolpyruvate, the PKM substrate.
=== Effects of pH === Most enzymes are sensitive to pH and have specific ranges of activity. All have an optimum pH. The pH can stop enzyme activity by denaturating (altering) the three-dimensional shape of the enzyme by breaking ionic, and hydrogen bonds. Most enzymes function between a pH of 6 and 8; however pepsin in the stomach works best at a pH of 2 and trypsin at a pH of 8.
2,6-Dichloro-1,4-benzoquinone, also known as 2,6-DCBQ, an organic compound that emerges as a disinfection by-product (DBP) that is frequently found in drinking water disinfected with chlorine or chloramines. 2,6-DCBQ is a member of the halobenzoquinones (HBQ), which in recent years has gained significant attention in environmental toxicology due to high levels encountered in drinking water. 2,6-DCBQ has been linked to neurodevelopmental toxicity due to reactive oxygen species formation inhibiting the PI3K/AKT/mTOR pathway. DCBQ does not only have high toxic potency but is also a potential carcinogen. 2,6-DCBQ is frequently used in biochemistry to study the QB-binding site in Photosystem II (PSII). It is used as an artificial electron acceptor (AEAs) with a molecular structure similar to plastoquinone's.
He also receives further instruction from Morpheus on subjects such as "freeing his mind" from the restrictions of the Matrix, essentially overcoming the physics engine the Matrix operates on. He is also informed of the existence of its agents, programs designed by the machines to maintain order and dominance over the human race, created with abilities such as dodging bullets, running at high speeds, jumping great distances, and physically possessing people in the Matrix. If killed, they simply find a new host to overcome. After several days aboard Morpheus' hovercraft, the Nebuchadnezzar, Neo is taken to meet the Oracle, who has the power of foresight within the simulated world. She tells him that he has the "gift", but appeared to be waiting for something, and that in his present life he is not the One. The Oracle warns him that a situation will arise when he will have to choose between saving his own life or that of Morpheus. Returning from the Oracle to a landline phone, which serves as the exit for "red pills" to leave the Matrix, the crew of Morpheus's ship is betrayed by Cypher, a "red pill" who is willing to give the agents Morpheus in exchange for the promise of being mentally erased and reconnected permanently to the Matrix as an escape from the real world's bleakness. In the Matrix, SWAT troops kill Mouse. Cypher jacks out and grabs a real-world lightning gun, injuring Tank and killing Dozer. He kills Apoc and Switch, who remain jacked in, by prematurely terminating their connections. In the Matrix, Smith defeats and captures Morpheus.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.